Previous 10 |
Allow ed Japanese Patent Application for Daily Ophthalmic Use of Nyxol to Improve Visual Performance R&D Funding for APX3330 and Pipeline Candidates with $1.7M NIH National Eye Institute Grant FARMINGTON HILLS, Mich.,...
FARMINGTON HILLS, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced the publication of two semin...
News, Short Squeeze, Breakout and More Instantly...
Ocuphire Pharma Inc Com Company Name:
OCUP Stock Symbol:
NASDAQ Market:
Ocuphire Pharma Inc Com Website:
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (N...
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today anno...
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial r...